Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure a report on behalf of the MDS clinical research consortium

Cancer

Volumn 121, Issue 6, 2015, Pages 876-882

  Jabbour, Elias J ^a   Garcia Manero, Guillermo ^a   Strati, Paolo ^a   Mishra, Asmita ^b   Al Ali, Najla H ^b   Padron, Eric ^b   Lancet, Jeffrey ^b   Kadia, Tapan ^a   Daver, Naval ^a   O'Brien, Susan ^a   Steensma, David P ^c   Sekeres, Mikkael A ^d   Gore, Steven D ^e   Dezern, Amy ^f   Roboz, Gail J ^g   List, Alan F ^b   Kantarjian, Hagop M ^a   Komrokji, Rami S ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g Cornell University ^*  (United States)

Author keywords

Hypomethylating agent failure; Low risk; Myelodysplastic syndrome; Survival

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; HYPOMETHYLATING AGENT; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER PROGNOSIS; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; INTERMEDIATE RISK PATIENT; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; UNSPECIFIED SIDE EFFECT; AGED; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; PROGNOSIS; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84924217874     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29145     Document Type: Article

References (21)

1. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009;361:1872-1885.
2. Bejar R, Levine R, Ebert BL, et al. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol. 2011;29: 504-515.
3. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
4. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429-2440.
5. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, openlabel, phase III study. Lancet Oncol. 2009;10:223-232.
6. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106:1794-1803.
7. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109:52-57.
8. Jabbour E, Garcia-Manero G, Batty N, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. 2010;116:3830-3834.
9. Prebet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29:3322-3327.
10. Duong VH, Lin K, Reljic T, et al. Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure. Clin Lymphoma Myeloma Leuk. 2013;13:711-715.
11. Prebet T, Thepot S, Gore SD, Dreyfus F, Fenaux P, Vey N. Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure. Haematologica. 2013;98:e18-e19.
12. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419-425.
13. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454-2465.
14. Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008;113:1351-1361.
15. Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008; 22:538-543.
16. Agresti A. Categorical Data Analysis. 2nd ed. Hoboken, NJ: John Wiley & Sons Inc; 1990.
17. Kaplan EL, Maier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
18. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34: 187-220.
19. Kelaidi C, Park S, Sapena R, et al. Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents. Leukemia. 2013;27:1283-1290.
20. Litzow MR, Tarima S, Perez WS, et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood. 2010;115:1850-1857.
21. Borthakur G, Ahdab SE, Ravandi F, et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma. 2008;49:690-695.